» Articles » PMID: 20937645

Metabolic Syndrome and Endometrial Cancer Risk

Overview
Journal Ann Oncol
Publisher Elsevier
Specialty Oncology
Date 2010 Oct 13
PMID 20937645
Citations 69
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Various studies reported direct associations between endometrial cancer risk and individual components of the metabolic syndrome (MetS), i.e. obesity, diabetes, hypertension, and dyslipidemia, but only a few epidemiological studies considered the association with MetS overall.

Methods: We analyzed data from a case-control study including 454 women with incident endometrial cancer and 798 controls admitted to the same hospitals as cases for acute conditions. Different definitions of MetS were considered, including a combination of self-reported history of diabetes, drug-treated hypertension, drug-treated hyperlipidemia, and various measures of (central) obesity. Odds ratios (ORs) were computed from unconditional logistic regression models, adjusted for major confounding factors.

Results: The multivariate ORs of endometrial cancer were 2.18 for type 2 diabetes, 1.77 for hypertension, 1.20 for hyperlipidemia, between 1.62 and 2.23 for various definitions of central obesity, and 3.83 for women with a body mass index (BMI) >30 kg/m(2). The risk of endometrial cancer was significantly increased for subjects with MetS, the ORs ranging between 1.67 and 2.77 when waist circumference was included in MetS definition, and 8.40 when BMI was considered instead.

Conclusions: This study indicates a direct association between various MetS components, besides overweight, with the risk of endometrial cancer.

Citing Articles

Evaluation of the impact of diabetes mellitus on endometrial cancer risk: an updated meta-analysis of case-control studies.

Drab A, Kanadys W, Malm M, Wdowiak K, Dolar-Szczasny J Arch Med Sci. 2025; 20(6):2056-2062.

PMID: 39967957 PMC: 11831351. DOI: 10.5114/aoms/196001.


Attitudes, beliefs and preferences surrounding home-based exercise programs in endometrial cancer patients receiving treatment.

Gorzelitz J, Adeagbo M, Dungan-Seaver S, Hill E, Kumar A, Goodheart M Gynecol Oncol Rep. 2025; 57():101659.

PMID: 39811828 PMC: 11730264. DOI: 10.1016/j.gore.2024.101659.


Novel metabolic prognostic score for predicting survival in patients with cancer.

Shi J, Liu C, Zheng X, Chen Y, Zhang H, Liu T Sci Rep. 2025; 15(1):1322.

PMID: 39779840 PMC: 11711642. DOI: 10.1038/s41598-025-85287-6.


Survival benefit of metformin use according to cancer diagnosis in diabetic patients with metabolic syndrome.

Park J, Moon S, Park H, Cho S Prev Med Rep. 2024; 48:102928.

PMID: 39634282 PMC: 11616528. DOI: 10.1016/j.pmedr.2024.102928.


Germline copy number variants and endometrial cancer risk.

Stylianou C, Wiggins G, Lau V, Dennis J, Shelling A, Wilson M Hum Genet. 2024; 143(12):1481-1498.

PMID: 39495297 PMC: 11576655. DOI: 10.1007/s00439-024-02707-9.